Lantheus Holdings (LNTH) Cost of Revenue (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Cost of Revenue came in at $146.4 million in Q1 2026, up 8.4% year-on-year from $135.1 million in Q1 2025, and down 11.75% on a QoQ basis from $165.9 million in Q4 2025.
Lantheus Holdings (LNTH) Cost of Revenue (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Cost of Revenue data on file, last reported at $146.4 million in Q1 2026.
- On a quarterly basis, Cost of Revenue rose 8.4% year-over-year to $146.4 million in Q1 2026; TTM through Mar 2026 was $611.0 million, a 10.58% increase from a year earlier, with the FY2025 full-year figure at $599.7 million, up 9.9% from the prior year.
- Cost of Revenue for Q1 2026 stood at $146.4 million, down from $165.9 million in the prior quarter.
- Over the last five years, Cost of Revenue for LNTH reached as high as $223.7 million in Q1 2023 and fell as low as $79.8 million in Q1 2022.
- Historically, Cost of Revenue has averaged $131.3 million across 5 years, with a median of $135.1 million in 2025.
- Across the five-year window, Cost of Revenue soared 180.3% in 2023 and plunged 42.72% in 2024, its largest moves.
- Year by year, Cost of Revenue stood at $96.0 million in 2022, then rose by 29.31% to $124.1 million in 2023, then grew by 14.85% to $142.6 million in 2024, then increased by 16.38% to $165.9 million in 2025, then slipped by 11.75% to $146.4 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $146.4 million in Q1 2026, $165.9 million in Q4 2025, and $161.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Lantheus Holdings | 7.04 Bn | 6.54 Bn | 230.92 Mn | 146.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.41 Mn |
| Mar 31, 2026 | 146.41 Mn |
| Dec 31, 2025 | 165.91 Mn |
| Dec 31, 2025 | 165.91 Mn |
| Sep 30, 2025 | 161.65 Mn |
| Sep 30, 2025 | 161.65 Mn |
| Jun 30, 2025 | 137.03 Mn |
| Jun 30, 2025 | 137.03 Mn |
| Mar 31, 2025 | 135.06 Mn |
| Mar 31, 2025 | 135.06 Mn |
| Dec 31, 2024 | 142.57 Mn |
| Dec 31, 2024 | 142.57 Mn |
| Sep 30, 2024 | 136.61 Mn |
| Sep 30, 2024 | 136.61 Mn |
| Jun 30, 2024 | 138.32 Mn |
| Jun 30, 2024 | 138.32 Mn |
| Mar 31, 2024 | 128.13 Mn |
| Mar 31, 2024 | 128.13 Mn |
| Dec 31, 2023 | 124.13 Mn |
| Dec 31, 2023 | 124.13 Mn |